Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026
Source: SeekingAlpha
2025-05-13 13:44:38 ET
More on Iterum Therapeutics
- Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
- Iterum Therapeutics Non-GAAP EPS of -$0.10
- Seeking Alpha’s Quant Rating on Iterum Therapeutics
- Historical earnings data for Iterum Therapeutics
- Financial information for Iterum Therapeutics
Read the full article on Seeking Alpha
For further details see:
Iterum targets ORLYNVAH US launch by Q4 2025 while extending cash runway into 2026
Iterum Therapeutics plc
NASDAQ: ITRM
ITRM Trading
1.0% G/L:
$0.1719 Last:
229,900 Volume:
$0.177 Open:
ITRM Latest News
ITRM Stock Data
$15,988,461
51,778,499
0.46%
14
N/A
Biotechnology & Life Sciences
Healthcare
IE
Dublin 1
